Novartis chairman joins Alcon's board
This article was originally published in Clinica
Executive Summary
Novartis is increasing its grip on eye care specialist Alcon, after its chairman Daniel Vasella was also elected chairman of Alcon's board. Novartis became Alcon's majority owner earlier this year, raising its stake in the firm to 77% (www.clinica.co.uk, 5 January 2010). However, Alcon's shareholders resisted the buy-out and Novartis is now battling them to buy the remaining 23%. Dr Vasella has served on Alcon's board since July 2008. He replaces Cary Rayment, who had been chairman since 2005. Earlier this month, former Novartis CFO Robert Karsunky became Huenenberg, Switzerland-based Alcon's CFO (www.clinica.co.uk, 5 October 2010).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.